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Abstract
While factors contributing to rates of approval and disapproval of preimplantation genetic
diagnosis (PGD) have been studied at length, the perspective of Physician Assistants’ (PA)
approval and disapproval of PGD has not been studied, nor the common reasons why PAs
approve or disapprove of PGD. The first goal of this study was to identify approval and
disapproval rates of PGD amongst PAs. The next goal was to identify common reasons PAs
approve or disapprove of PGD utilization. Members of the California Academy of Physician
Assistants [CAPA (CA)] and Kansas Academy of Physician Assistants [KAPA (KS)] completed
an adapted, electronic survey that assessed individual approval and disapproval rates of PGD,
and the common reasons why. Regarding the use of PGD, 43% of the participants agreed or
strongly agreed with the use of PGD for Mendelian conditions. The most common reasons
participants agreed were: PGD improves the chances of a healthy child and couples’ autonomy.
Most commonly cited reasons of disapproval of the Mendelian use of PGD were: PGD interferes
with nature and places providers in the role of “Playing God”, and PGD promotes discrimination.
Opinions regarding Non-Mendelian use of PGD were more stratified, with 93% disagreeing or
strongly disagreeing with PGD utilization for Non-Mendelian screening. The common reasons
of disapproval of PGD were: PGD promotes discrimination against people with certain
characteristics, PGD interferes with nature and places providers in the role of “playing God”,
widespread use of PGD may lead to unforeseen consequences, and PGD leads to unnecessary
destruction of embryos.
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Chapter 1: Introduction
Introduction
The following chapter will highlight the history of reproductive genetics, advancements
in reproductive technology, and preimplantation genetic diagnosis (PGD). This chapter outlines
the background, problem statement, purpose, significance, research questions, and definitions of
terms of this study.
Background
The understanding of genetics began in 1865 with Gregor Mendel (National Human
Genome Research Institute, 2014). Historically considered the father of genetics, Mendel
discovered that traits are transmitted in discrete units called genes, along with inheritance
patterns. The discovery of inheritance patterns supported Charles Darwin’s notion of natural
selection in 1859, which explained that the genetics best fit for survival will be inherited in
subsequent generations (National Human Genome Research Institute, 2014).
Discovery and advancements in the understanding of genetics have allowed for
reproductive genetic technology to make extensive progress. The first trial experiments of invitro fertilization (IVF) procedures were conducted in the early 1900’s (Franasiak & Scott, n.d.).
Since the first successful IVF birth in 1978, the development of IVF enabled the research and
understanding of embryo development (Franasiak & Scott, n.d.). IVF played a central role in
advancing infertility success and helping couples achieve successful pregnancies (Franasiak &
Scott, n.d.). On the basis of IVF, technologies have advanced to implement embryo screening
and selection (Franasiak & Scott, n.d.). The procedure of screening, distinguishing, and
selecting embryos that are reproductively competent and free from genetic diseases or
chromosomal defects is known as preimplantation genetic diagnosis (PGD) (Franasiak & Scott,

8

n.d.). PGD can identify the presence of chromosomal translocations and single-gene disorders
(Fertility Center of New England, n.d.). The goal of PGD is to distinguish those embryos that
are capable of producing a healthy child from those that cannot in order to improve rates of
successful pregnancies, while minimizing risk of genetic or chromosomal complications, and
miscarriages and pregnancy terminations (abortions) (Franasiak & Scott, n.d.). In 1990, the first
successful child following PGD was born (Franasiak & Scott, n.d.). Thereafter, PGD technology
has advanced with expanded indications and worldwide utilizations (Franasiak & Scott, n.d.).
With advancements in genetics, specifically embryonic research, ethical controversies
emerge. PGD is no exception. A wide spectrum of understandings, perspectives, and ethical
considerations manifest, with respect to PGD utilization, both in the general population and in
the medical community. Preimplantation genetic screening (PGS) uses one aspect of the PGD
process, allowing for identification of aneuploid embryos. PGD includes this aneuploidy
screening, and adds additional testing for other genetic markers (Weissman et al., 2017; Fertility
Centers of New England, 2013). A study conducted by Weissman et al. (2017) analyzed the
applications for PGS and factors influencing the utilization and restriction of PGS worldwide.
Results of the study showed that utilization of PGS were largely for women older than the age of
35 and women with a history of implantation failure or recurrent pregnancy loss (Weissman et
al., 2017). Factors inhibiting worldwide use of PGS included legislation, low demand, and
cost/staffing considerations (Weissman et al., 2017). Of IVF clinic respondents, a majority
believed PGS could prevent transfer of aneuploid embryos and increase live birth rates while
conversely reducing miscarriage rates (Weissman et al., 2017).
Diving deeper than the utilizations and restrictions of PGS and PGD, a Princeton Survey
Research Associates conducted a United States survey in 2002 to address public awareness and
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attitudes on genetic testing. Most commonly supported reasons for using PGD included:
avoiding serious genetic disease such as autosomal dominant conditions, ensuring a child was a
blood match of the ABO and Rh factor to that of the living sibling for potential transfusions and
transplantations, and avoiding genetic diseases such as cancer, cystic fibrosis, Huntington
Disease, or sickle cell disease (Princeton Survey Research Associates, 2002). The majority of
respondents approved IVF and prenatal testing for genetic diseases or chromosomal defects
(Princeton Survey Research Associates, 2002).
Other perspectives exist within the general public regarding the use of PGD. A metaanalysis of public perspectives towards using PGD to detect hereditary cancers, revealed a lack
of knowledge and understanding of PGD (Quinn, Pal, Murphy, Vadaparampil, & Kumar, 2011).
About one third of respondents had no knowledge about PGD (Quinn et al., 2011). A majority
believed PGD should be offered to those affected by hereditary cancers, and half would consider
personally using PGD if a hereditary cancer was a concern (Quinn et al., 2011).
Based on a 2013 survey by Harris Interactive Service Bureau, public perspectives on
PGD varied (Winkelman, Missmer, Myers, & Ginsburg, 2015). A majority favored PGD,
especially for the purpose of reducing fatalities early in life and eliminating lifelong disabilities
(Winkelman et al., 2015). The most common reasons for favoring PGD were that couples should
have reproductive autonomy and improve the chances of a healthy child. Those opposing PGD,
commonly did so because PGD interferes with nature, and widespread PGD use may lead to
unforeseen consequences (Winkelman et al., 2015).
In addition to evaluating public perspectives, physician viewpoints on PGD have also
been studied. Specific specialties that have been screened include internists, pediatricians,
genetic professionals, neurologists, psychiatrists, obstetricians, and gynecologists. A 2012
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United States survey by Klitzman et al. (2013), revealed internists were most likely to
recommend PGD for cystic fibrosis patients (33.7%) and breast cancer patients (23.5%). Based
on a Chicago qualitative study of pediatricians and parents by Campbell & Ross (2004),
pediatricians were more hesitant than parents to screen for genetic links to criminal behavior.
Another study revealed only a small percentage (2.4%) of psychiatrists and neurologists
discussed PGD with their patients (Abbate et al., 2014). Psychiatrists and neurologists were
most likely to refer to PGD for Huntington's disease, Tay-Sachs, and cystic fibrosis (Abbate et
al., 2014). In a 2010 United States survey, only 17% of obstetricians and gynecologists felt like
they were knowledgeable about PGD (Abbate et al., 2014). Physicians’ support for PGD was
highest with the aim to avoid serious and life-threatening genetic diseases, and lowest when
considering less serious diseases or sex selection. A general trend for the need for increased
provider education was also observed (Abbate et al., 2014).
Problem Statement
Several research studies have been conducted analyzing both the general public’s and
physicians’ perspectives, understandings, and ethical considerations about PGD. Currently, no
clear consensus exists in the public or medical community for when, how, or why PGD should or
can be used. Amidst the literature, research on PAs’ approval and disapproval of PGD use for
Mendelian vs. Non-Mendelian disorders and the common reasons of approval and disapproval of
the utilization of PGD is absent. This lack of research raises the importance of obtaining data of
PAs’ understanding and opinions towards PGD. Our study aimed to fill this void.
Purpose of the Study
The purpose of this study was to survey members of California Academy of Physician
Assistants [CAPA (CA)] and members of Kansas Academy of Physician Assistants [KAPA
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(KS)] regarding the percentage of PAs that approve and disapprove of PGD use for Mendelian
vs. Non-Mendelian disorders, and the common reasons that PAs approve and disapprove the
utilization of PGD. Furthermore, this study analyzed the understandings that PAs have of the
PGD definition and process.
Significance of the Study
As indicated from data conducted by the NCCPA (2016), the PA profession has grown
35.9% from 2010-2015. According to the Bureau of Labor Statistics, the projected growth of
PAs is 37% from 2016 to 2026 (“2015 Statistical profile,” 2016 & Bureau of Labor Statistics,
2017). Due to this large expansion of practicing PAs, in combination with the continuing
advancements in reproductive technology and PGD, it will be increasingly important for PAs to
understand PGD and be able to discuss PGD effectively with their patients (Hudson, 2006).
Research conducted by Hudson (2006) indicated that as the general public gains
knowledge about advancing reproductive technology, their perspectives, understandings, and
ethical considerations on PGD utilization fluctuated. Many misconceptions exist, regarding the
development and purpose of PGD. With increased general public interest in PGD, the role of the
PA is crucial in educating and guiding patients (Hudson, 2006). Regardless of the field in which
a PA may work, patients with inheritable conditions will present to them for care. These patients
may want to reproduce but have fertility difficulties or risk of passing on genetic conditions
(Hudson, 2006). Because PAs provide education and guidance to patients on a variety of topics,
including reproductive medicine and genetic diseases, PA knowledge about PGD is essential
(Abbate et al., 2014; Hudson, 2006).
The understanding of PGD is critical for PAs, as well as all medical providers, as
potential controversies arise. This study provided information about the current percentage of
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PAs that approve and disapprove of PGD use for Mendelian vs. Non-Mendelian disorders and
the common reasons that PAs approve and disapprove of the utilization of PGD, which could
provide insight for the future when considering how PAs can be educated to effectively address
the topic of PGD with patients.
Research Questions
This study attempted to answer the following research questions:
1. What is the percentage of PAs that approve of PGD use for Mendelian vs. NonMendelian disorders?
2. What is the percentage of PAs that disapprove of PGD use for Mendelian vs. NonMendelian disorders?
3. What are the most common reasons PAs approve the use of PGD?
4. What are the most common reasons PAs disapprove the use of PGD?
Definition of Terms
The following definition of terms are essential to understanding this study.
Chromosomal abnormality: result from mutations which change the number of chromosomes
(numerical abnormalities) or change the structure of the chromosome (structural abnormalities).
Chromosomal abnormalities may alter the ability of the cell to survive and function
(“Chromosome abnormalities,” 2017).
Embryo: the early developmental stage of an animal following conception until the end of the
seventh week since conception (“Embryo,” 2016).
Gene Probe: a unique probe that is custom designed for each couple to analyze the DNA from
the cells removed from the embryo, for the specific gene mutation at specific loci in short
tandem repeats. (“Preimplantation Genetic Diagnosis,” n.d.; “Karyomapping,” 2014).
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Genetic disorder: a disease caused by a change in the DNA sequence from the normal sequence.
Genetic disorders from a mutation in one gene, mutations in multiple genes, combination of gene
mutations and environmental factors, or by damage to chromosomes. (“Frequently asked
questions,” 2015).
In vitro fertilization (IVF): fertilization of a human egg in laboratory dish or test tube.
Specifically, fertilization occurs by mixing sperm with eggs, surgically removed from an ovary.
The sperm fertilizes the egg to create an embryo, which is transferred into a prepared uterus (“In
vitro fertilization,” 2017).
Karyomapping: involves a technique of genome-wide linkage analysis, in which numerous single
nucleotide polymorphisms (SNP) within the genome are genotyped in the two parents and their
embryos to determine whether an embryo has a genetic defect (Gimenez et al., 2015).
Mendelian disorder: a genetic disease showing a specific pattern of inheritance by means of
dominant and recessive alleles, resulting from a single mutation in the structure of DNA at one
genetic locus, which creates a single basic defect that has some pathological consequence(s)
(“Mendelian disorder,” n.d.).
Non-Mendelian condition: any complex genetic disease-e.g., hypertension, diabetes mellitus,
arteriosclerotic heart disease, which does not follow a simple mendelian pattern of inheritance
and involves more than one gene (“Nonmendelian disorder,” 2002).
Physician assistant (PA): is a nationally certified and state-licensed medical professional (“What
is a PA?,” n.d.).
Polymerase chain reaction (PCR): an in vitro technique for rapidly synthesizing large quantities
of a specific DNA segment that involves separating the DNA into its two complementary
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strands. Utilizing DNA polymerase to synthesize two stranded DNA from each single strand,
and repeating the process numerous times (“Polymerase chain reaction,” n.d.).
Preimplantation genetic diagnosis (PGD): is defined as the testing of preimplantation stage
oocyte polar bodies and zygotes/embryos for chromosomal defects and genetic defects with the
use of karyomapping or a gene probe (Geraedts & De Wert, 2009).
Preimplantation genetic screening (PGS): screening to identify de-novo aneuploidy, including
subchromosomal deletions and additions, in embryos of couples known (or presumed) to be
euploid (Schattman & Kangpu, 2017).
Conclusion
As stated in the problem statement, purpose, and significance of this study, the
importance of improving understandings of PGD and PA knowledge and views of PGD is
apparent. The literature review in Chapter Two will define PGD, describe the history of PGD,
indications and utilizations for the procedure, and the process of PGD technique. Chapter Two
introduces the ethical controversies surrounding PGD regulations and utilizations. A majority of
the next chapter will discuss past research, which analyzes both the general public’s and
physicians’ understandings and perspectives towards PGD.
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Chapter 2: Literature Review
Introduction
Preimplantation genetic diagnosis (PGD) is a procedure which analyzes the genetic
makeup of single cells biopsied from oocyte polar bodies or embryos, formed through in vitro
fertilization (IVF) (Traeger, 2017). The embryos are screened to determine any chromosomal
abnormalities. Normal embryos are selected for transfer to the prepared uterus. The goal is to
eliminate chromosomal/genetic defects and achieve an unaffected pregnancy (Khalaf, 2007).
PGD was developed to aid couples with an unsuccessful reproductive history and couples whose
potential offspring may be at a genetic risk for Mendelian disorders, mitochondrial disorders, or
structural chromosome abnormalities (Geraedts & De Wert, 2009).
PGD is a multi-step procedure overseen by a collaboration of specialized gynecologists,
embryologists, and geneticists (Traeger, 2017). The process of PGD involves close collaboration
between reproductive endocrinologists who are experts in assisted reproduction, embryologists
who specialize in embryo biopsy and germ cell details, and geneticists who specialize in the
genetic analysis at the single-cell level (Traeger, 2017). PGD is considered a form of prenatal
diagnosis (Traeger, 2017). The utilization of PGD advances beyond previous prenatal diagnosis
techniques. The most common forms of prenatal testing are amniocentesis or chorionic villi
sampling, which involve testing the chromosomal makeup of a developing fetus for abnormal
chromosomal conditions. These methods accurately identify chromosomal disorders during
pregnancy (Traeger, 2017). If defects are discovered, difficult decisions for parents may be
provoked. According to Traeger (2017) and Bick & Lau (2006), the advantage of PGD is that it
supported the selection of a normal embryo prior to implantation which substantially reduced the
considerations of terminating an affected pregnancy.
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Countless opinions exist both supporting and opposing PGD. This literature review
analyzes understandings and perspectives of the public and medical communities. This chapter
will introduce the history, laboratory process, indications, and uses of PGD. After addressing the
ethical considerations and regulations regarding PGD, the literature review will discuss past
research, present research, and worldwide perspectives on the use of PGD with regard to the
general public and physicians.
History of Preimplantation Genetic Diagnosis
In the late 19th century, Sir Walter Heape, a professor at the University of Cambridge in
the United Kingdom, introduced the concept of assisted reproductive technologies by
successfully transplanting rabbit embryos (Kamel, 2013). In 1934, this concept of experimenting
with assisted reproduction was revisited. After mixing rabbit sperm and egg in vitro, Gregory
Pincus, PhD, implanted the developing embryo into a rabbit (Kamel, 2013). Between 1944 and
1948, Dr. John Rock, a clinical professor at Harvard Medical School, and his assistant Miriam
Menkin, completed a series of human embryo IVF experiments (Countway Repository, 2009).
Although not successful for human life, this sparked the progression of human IVF development
(Countway Repository, 2009).
In 1966, the first karyotype following amniotic fluid sampling was performed
(Vermeesch, Voet, & Devriendt, 2016). In 1967, the first prenatal karyotype of a chromosomal
abnormality was identified (Vermeesch, Voet, & Devriendt, 2016). In 1968, the possibility of
PGD in animals was prompted (Vermeesch, Voet, & Devriendt, 2016). In 1973, the first human
IVF pregnancy was reported in Australia, but was unsuccessful after one week (Kamel, 2013).
Subsequently, in the UK, Patrick Christopher Steptoe, MD, and physiologist Robert Geoffrey
Edwards created the first “test-tube baby” (Kamel, 2013). In July 1978, Lesley Brown gave birth
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to a healthy baby girl, Louise Brown, which was a breakthrough in assisted human reproductive
technology (Kamel, 2013). The success of IVF enabled the success of PGD on human embryos,
among other reproductive technologies (Kamel, 2013).
In 1980, Alan Handyside, PhD, of the United Kingdom introduced PGD to identify
chromosomal defects in embryos by cell biopsy (Kamel, 2013). The process of cell biopsy was
developed as an alternative to post-implantation prenatal testing. In 1989, the first report was
published on biopsying a pre-implanted embryo and detecting the sex using DNA amplification
(Kamel, 2013). The first applications for PGD were used to test monogenic disorders and sexlinked disorders, which was made possible by Elana Kontogianni’s work showing polymerase
chain reaction (PCR) for the Y chromosome was possible from a blastomere (Franasiak & Scott,
n.d.). Researchers were able to focus on X-chromosome linked diseases by amplifying and
detecting the Y-chromosome specific repeat sequences to select for embryos that were female;
thus, not affected by the X-linked disease. Original approaches to such discoveries led to newer
technologies that detected gene mutations on autosomes and sex chromosomes, allowing for the
selection of mutation free embryos for transfer in pregnancy (Franasiak & Scott, n.d.). In 1990,
Handyside and colleagues assisted with the first successful childbirth following PGD for sex
selection of embryos in attempt to avoid an X-linked genetic disorder (Kamel, 2013). As the
first polar body biopsy for PGD, this involved selecting for the female embryos to eliminate the
risk of male embryos being affected by the X-linked defect (Kamel, 2013). In 1992, the first live
births occurred after identifying and selecting against the autosomal recessive disorder, cystic
fibrosis (Kamel, 2013). In 1999, the first pregnancy was successful when PGD was used to
select an embryo free from sickle cell anemia (Kamel, 2013). In 2001, PGD was used to select
offspring that would have the potential to be a donor to siblings in a family with severe blood
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disorders (Vermeesch, Voet, & Devriendt, 2016). Then in 2013, genome-wide haplotyping, or
karyomapping, was commercialized by a company called Illumina, allowing a new method for
selecting against embryos carrying Mendelian inherited disorders (Griffin & Gould, 2017).
Traditionally, the detection of single gene disorders in cells biopsied from
preimplantation embryos has been done through a sensitive multiplex, PCR methodology in
order to amplify specific DNA fragments to detectable concentrations (Gimenez et al., 2015).
PCR amplification of the DNA allows for detection of the gene mutation site and/or linked
polymorphisms. Problems within the amplification process exist such as allele drop out, which
is failure to amplify one of the two parental alleles in the biopsied cell, and DNA contamination.
Current standard practice guidelines recommend using both amplification and analysis of several
closely linked polymorphisms, along with direct mutation detection (Gimenez et al., 2015). The
process of optimizing a multiplex-PCR capable of amplifying all of the necessary loci from a
single cell requires a significant amount of laboratory work developing a specific test for each
patient, which can take months and higher costs (Gimenez et al, 2015). In the past, an older
technology was used requiring development of a physical DNA probe which was used to test the
embryos and now the term “probe,” is a relatively outdated term (ORMgenomics, n.d.).
Invented in 2008 and commercialized in 2013, karyomapping was developed as the
newest alternative to conventional PCR methods for PGD (Gimenez et. al, 2015; Griffin &
Gould, 2017). The introduction of karyomapping not only greatly reduced the time required for
embryonic testing prior to transfer, but also improved the accuracy of PGD (Gimenez et. al,
2015; ORMgenomics, n.d.). For all 23 pairs of chromosomes, karyomapping uses a universal set
of markers across the whole genome (ORMgenomics, n.d.). These markers allow for the
disease-causing gene to be located and tracked from parents to embryo (ORMgenomics, n.d.).
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Rather than designing family-specific, and disease-specific tests for each couple, karyomapping
allows for a single test to be applicable to all families for a majority of conditions
(ORMgenomics, n.d.). This shift is due to the use of universal markers, which are spread across
the genome (ORMgenomics, n.d.).
The process in karyomapping involves genome-wide linkage analysis, in which hundreds
of thousands single nucleotide polymorphisms (SNP) within the genome are genotyped in the
two parents and their embryos (Gimenez et al., 2015). Inheritance of chromosomal segments
with the genes they contain can be followed down generations due to each chromosomal region
having a unique SNP fingerprint. The SNP fingerprint of the parents can be compared to other
family members with known genetic status, for example, another relative that is known carrier of
the same mutation as of the parents. After analysis of the family genomes, a unique DNA
fingerprint can be identified for that family using the combination of SNP alleles associated with
a chromosome carrying a gene mutation (Gimenez et al., 2015). Embryos can then be tested
against the DNA fingerprint to determine if they carry the normal or mutated gene, and the
embryo carrying the SNP pattern mutation can be avoided for pregnancy (Gimenez et al., 2015;
ORMgenomics, n.d.).
Karyomapping is a routine procedure for PGD which serves to be a powerful and
versatile new approach for diagnosing single gene disorders in embryos. According to Gimenez
et al. (2015), the karyomapping process allows for the possibility to expand past linkage analysis
and provide direct detection of mutations, previously unseen by conventional PGD methods.
Although karyomapping is not widely used yet for aneuploidy screening, researchers confirm
karyomapping has the potential to combine strategies and provide aneuploidy screen and
identification along with monogenic defects (Gimenez et al., 2015; Griffin & Gould, 2017). Due
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to limited reliability detecting post-zygotic trisomy, karyomapping has not been fully
implemented clinically for chromosomal aneuploidy screening (Griffin & Gould, 2017). As of
2017, karyomapping is currently used for the detection of monogenic disorders at approximately
1000 clinics worldwide (Griffin & Gould, 2017).
Cell Acquisition and Extraction
The following paragraphs will discuss the complex process of PGD, explaining how
embryos are screened and selected during the initial stages of growth prior to implantation. The
process of IVF and PGD begins when oocytes are collected from the female and sperm are
collected from the male and both are then taken to the laboratory (Alberts et al., 1983). The
oocyte is surrounded by an extracellular matrix, the zona pellucida. The acrosome of the sperm
releases enzymes that lyse a portion of the zona pellucida, thus permitting the penetration of the
egg by a single sperm resulting in the fusion of the sperm and the egg (Alberts et al., 1983).
After fusion of the membranes, the haploid sperm nucleus combines with the haploid egg
nucleus, producing a diploid nucleus of a fertilized egg, the zygote (Gilbert, 2000).
For approximately three days, the zygote is maintained on a laboratory dish until it
reaches the eight-cell stage. At this point, biopsy is safe and can be performed because the
removal of cell(s) will not have detrimental effects on the growth of the embryo (Antonios,
2011). Polar-body biopsy, cleavage-stage biopsy, or blastocyst biopsy are the three most
commonly used techniques to remove a cell or cells from the embryo for analysis (Thornhill &
Snow, 2002). These processes share a similar step of opening the zona pellucida via either sharp
microneedle, acidified Tyrode's solution with a pH 2.2, or by thermal ablation with a non-contact
laser. The cell(s) are removed by a micropipette or a hydraulic base suction system (Thornhill &
Snow, 2002).
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Polar-body biopsy, cleavage stage biopsy, and blastocyst trophectoderm biopsy are the
three most commonly utilized extraction methods to obtain a cell or multiple cells for their
genetic information for further analysis (Kuliev & Rechitsky, 2011). Kokkali et al. (2007)
compared cleavage stage biopsy and blastocyst biopsy methods by comparing 20 embryos of 20
couples, all affected by β-thalassaemia. The embryos were placed into two groups, one
undergoing cleavage stage biopsy and the other blastocyst biopsy. In the conclusion of this
study, cleavage stage biopsy and polar body biopsy, which remove one or two cells from the
embryo, resulted in a lack of genetic material available for amplification, while the blastocyst
biopsy resulted in larger amounts of genetic material for analysis.
The lack of genetic material for amplification indicates that the embryo is still viable for
implantation but utilizing PGD would be difficult to complete due to the lack of genetic material
for analysis (Kuliev & Rechitsky, 2011). Only 75.2% of cases utilizing cleavage stage biopsy
and polar body biopsy had enough genetic material due to only removing one or two cells for
genetic analysis (Kuliev & Rechitsky, 2011). Having only one or two cells’ genetic material
often results in inadequate amplification during each cycle of PGD (Kuliev & Rechitsky, 2011).
Utilizing the blastocyst biopsy, where the embryo is cultured for a longer period prior to removal
of four to five cells, resulted in 94.3% of cases having enough genetic material for accurate
amplification (Kuliev & Rechitsky, 2011). The amplification process has more genetic material
for testing, decreasing the likelihood of amplification failure. As a result, the PGD process is
able to obtain enough genetic material for amplification and accurate genetic analysis utilizing
blastocyst biopsies (Kokkali et al., 2007).

22

Indications and Utilizations for Preimplantation Genetic Diagnosis
A 2017 national survey by the Center for Disease Control revealed that 4% of 208,604
cycles of IVF in the US involved PGS and/or PGD (Weissman et al., 2017). The Society for
Assisted Reproductive Technology reported that 165 out of 458 (36%) participating clinics used
PGD, PGS, or both (Weissman et al., 2017). According to Weissman et al. (2017), this data is
likely an underestimation. Due to the increasing popularity of PGD and PGS and due to no
updated data available, the researchers estimate over 20% or more of IVF cycles in the US
currently involve PGS or PGD (Weissman et al., 2017).
Initially, PGD was used for the selection of embryos for couples who were carriers of
sex-linked diseases, and for determination of gender (IVF-Worldwide, n.d.). PGD quickly
progressed and today is indicated for identifying single gene mutations, structural chromosomal
abnormalities, abnormal number of chromosomes, tissue/human leukocyte antigen type, and
gender (IVF-Worldwide, n.d.). PGD can be considered for women of advanced maternal age
>35, couples with recurrent miscarriages, several failed IVF cycles, or prior pregnancy with a
chromosome abnormality, or where at least one partner has aneuploidy mosaicism or is a carrier
of an X-linked disease or structural chromosome rearrangement (IVF-Worldwide, n.d.). PGD is
intended for men who test positive to aneuploidy sperm screening or with infertility requiring
intracytoplasmic sperm injection (IVF-Worldwide, n.d.). PGD is most commonly used to
identify autosomal dominant diseases such as familial hypercholesterolemia, polycystic kidney
disease, or Huntington's disease. PGD is used to detect autosomal recessive diseases such as
sickle cell anemia, cystic fibrosis, or Tay-Sachs disease. PGD can identify X-linked diseases of
Duchenne muscular dystrophy or hemophilia, or chromosomal abnormalities such as Down
Syndrome (IVF-Worldwide, n.d.). PGD can also be used to diagnose late-onset diseases and
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predisposition syndromes such as cancer risk factors or Huntington’s disease. For example,
PGD can be used to find BRCA1 and BRCA2, hereditary breast and ovarian cancer genes, by
allowing parents to choose embryos free from these genes decreasing risk for offspring to later
develop the cancers (IVF-Worldwide, n.d.). The list of diseases, conditions, and syndromes that
PGD can detect is extensive and is continuing to expand with advances in reproductive and
genetic technologies.
As the utilization of PGD increased throughout the 2000’s, Johns Hopkins Public Policy
Center conducted a survey in 2008 on the prevalence and patterns of PGD usage in the United
States (Stern, 2014). The study analyzed the number of advanced reproductive clinics in the
United States utilizing PGD for aneuploidy testing, single gene disorders, structural chromosome
rearrangements, X-linked disease, non-medical sex selection, avoidance of adult onset disorders,
human antigen leukocyte typing, and selection for disability (Stern, 2014). The survey was sent
to 415 clinics with responses from 186 clinics, of which, 137 clinics offered PGD services. Of
these clinics, 82% performed IVF with PGD. The clinics provided 28% of testing services for
adult onset disorders such as Huntington's Disease, hereditary breast and ovarian cancer, and
Alzheimer’s Disease. Of the clinics surveyed, 23% provided IVF/PGD for human leukocyte
antigen typing; those intending to have another child who is an immunological match for a
sibling that is ill. The survey data indicated 6% of the clinics provided testing services with the
intention of having a child who is a match for an older sibling, where the new child is not at risk
for having the disorder (Stern, 2014). Additionally, the study found that 42% of the clinics
provided services of non-medical sex selection (Stern, 2014). Lastly, 3% responded that PGD
was utilized for the purpose of selection of embryos for a specific disease or disability, such as
deafness or dwarfism (Stern, 2014).
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Ethical Considerations
Each indication for PGD evokes associated ethical considerations. Initially, the primary
use of PGD testing was for Mendelian disorders, which includes genetic diseases such as cystic
fibrosis, Huntington Disease, or sickle cell disease (Imudia & Plosker, 2016). This indication
tends to produce fewer controversial arguments, as it involves testing the embryos for diseases
that can be detrimental to the offspring (Imudia & Plosker, 2016). Use of PGD for NonMendelian conditions creates more controversial considerations (Imudia & Plosker, 2016). NonMendelian conditions include: human leukocyte antigen typing, non-medical sex selection, nonmedical trait selection, and selection of embryos for disability and disease (Stern, 2014); (Boyle
& Savulescu, 2001); (“Nonmendelian disorder,” 2002).
Human leukocyte antigen typing is a potential use of PGD that is categorized under NonMendelian conditions. The testing and development of the “savior sibling” involves using PGD
to screen and select an embryo to be a genetic match to a living sibling (Stern, 2014, pp. 280309). The embryo is implanted with the intention of utilizing a stem cell or organ donation to
“save” the sibling (Stern, 2014). The ethical considerations surrounding human leukocyte
antigen typing include: the “savior sibling” having the capacity to consent or object to serve as
the donor, the best interest of the “savior sibling,” and if the “savior sibling” will be loved (Stern,
2014).
According to Boyle & Savulescu (2001), couples requesting human leukocyte antigen
typing love and appreciate the child, the child feels value in saving the life of the sibling, and
there are minimal psychological effects from being the “savior sibling.” In the United Kingdom,
the Human Fertilisation and Embryology Authority, HFEA, reports that PGD is approved for the
use of “savior siblings,” if the child born after PGD is at risk of also having the condition the
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existing child is experiencing (Robertson, 2003, pp. 465-471). For example, human leukocyte
antigen typing is approved for Fanconi’s anemia, but not for the use of childhood leukemia or
lymphoma without genetic mutation (Robertson, 2003). A study conducted by Johns Hopkins
Institutional Review Board in April 2004, found that 66% of 6,000 general public participants
approved of utilizing PGD for human antigen leukocyte typing (Hudson, 2006). Additionally,
supporters of PGD for human antigen leukocyte typing stated that use of PGD would fulfill two
functions: the selection of disease-free embryos and the selection of a compatible stem cell donor
(Boyle & Savulescu, 2001).
Another Non-Mendelian use of PGD is non-medical sex selection, which poses the
question of gender bias (Boyle & Savulescu, 2001). The argument opposing the use of PGD for
non-medical sex selection is that selecting for preferred gender could lead to imbalance of the
sexes in the population (Robertson, 2003). For example, many countries have the preferred sex
of the first child to be a male (Robertson, 2003). If sex-selection through PGD was utilized
frequently in these countries, the sex ratio would become unequal in certain populations
(Robertson, 2003). Perspectives on the use of PGD for gender selection is mixed. An article by
Robertson (2003), stated that utilizing PGD for the selection of a couple’s first child is
oftentimes labeled as sexist, due to the highly preferred gender the couple is requesting
(Robertson, 2003). However, Robertson (2003) stated that if a couple already has one child
conceived without the use of PGD for gender selection, subsequent children obtained through
PGD would not be labeled as a sexist selection. For example, if a couple has two male children,
and utilizes PGD to have a female child, this would not be labeled as sexist. However, if a
couple were to utilize PGD to have their first child, this would be labeled as sexist because of the
high rate of male preference, primarily seen in India and China (Robertson, 2003). The
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American Society of Reproductive Medicine, ASRM, stated that sex selection through PGD
should be “discouraged” as there is not enough evidence about the topic (Robertson, 2003, pp.
465-471).
An additional ethical consideration arises with using PGD for non-medical trait selection.
The use of PGD for non-medical trait selection is an attempt to choose traits of parental
preference and to help the child “have every possible advantage” (Hudson, 2006). In a study
conducted by Winkelman, Missmer, Myers, and Ginsburg, a survey of 1006 respondents of the
general population responded with 14.6% approval rate of PGD for physical selection and 18.9%
approval rate of PGD for personality traits (2015). However, utilizing PGD for non-medical trait
selection, poses the ethical consideration of “playing God” (Boyle & Savelescu, 2001, pp. 12401243). Johns Hopkins Institutional Review Board in April 2004, found that 72% of 6,000
participants disapprove of utilizing PGD testing for non-medically related traits (Hudson, 2006).
The Bioethics Council in the United States, reported that “human reproduction is a ‘gift’ and that
any form of selection or manipulation turns the child into a ‘manufacture’ and thus impairs
human flourishing” (Robertson, 2003, pp. 465-471). Once selection of traits becomes frequently
requested, the concept of “designer babies,” which involves the selection of preferred genes the
embryo will utilize for development, will result in non-medical trait selection to become even
more controversial. Additionally, non-medical trait selection and the future possibility of
“designer babies” poses the possibility of reduced genetic diversity (Boyle & Savulescu, 2001).
The selection of embryos for disability and disease bring about another issue related to
the use of PGD. Certain couples prefer their children to have the same condition affecting the
parents, thus selection of that embryo can ensure the child will have the desired condition
(Cooper & Jungheim, 2010). For example, a couple with dwarfism, recognized as a disability
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under the Americans with Disabilities Act of 1990, may undergo PGD with the desire of
choosing an embryo that would also have dwarfism, oftentimes reasoning that the disability
“culture” will be preserved (Cooper & Jungheim, 2010). Additionally, couples report that
relating to the child will be easier if the condition is shared (Cooper & Jungheim, 2010). The
selection of a disease or disability for the unborn child is controversial, as one is choosing to give
the child a disability instead of “enhancing their life” (Boyle & Savulescu, 2001, pp. 1240-1243;
Cooper & Jungheim, 2010).
Preimplantation genetic diagnosis testing for disorders which present in adulthood is less
controversial than previously discussed indications because the testing may decrease or eliminate
the chance of developing a disorder later in adulthood (Boyle & Savulescu, 2001). Typically, the
genetic analysis for adulthood conditions involves screening for specific genes known to be
associated with adult onset conditions (Stern, 2014). If the specific gene(s) are present, the
embryo will likely not be transferred, depending on the couple’s wishes (Boyle & Savulescu,
2001). For example, screening may be completed for Huntington's Disease, BRCA1 and
BRCA2, and markers to Alzheimer’s disease. If found, the embryo would not be transferred to
decrease the possibility of the resulting offspring developing said condition (Stern, 2014). PGD
was not widely utilized for adult onset diseases, with Johns Hopkins Public Policy Center
reporting 28% of 137 clinics provide such services (Stern, 2014). The ethical controversy
surrounding the genetic testing for adult onset disorders is minimal and often combined with
PGD use for genetic analysis of Mendelian diseases (Hudson, 2006).
According to Robertson (2003), the use of PGD for Mendelian diseases is typically the
least controversial indication, which involves testing of embryos for detrimental diseases, such as
cystic fibrosis, Tay-Sachs disease, and sickle-cell anemia. PGD was first utilized experimentally
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to eliminate the possibility of inheriting X-linked diseases. The first successful birth after using
PGD to identify Mendelian diseases and select a healthy embryo occurred in 1990 (Kamel,
2013). Since then, the use of PGD for Mendelian diseases has continued to increase because
ethical controversies regarding this category have remained minimal (Robertson, 2003). Johns
Hopkins Institutional Review Board conducted a study in April 2004 and found that 68% of
6,000 participants approved of embryo selection to prevent fatal childhood illness (Hudson,
2006).
Regardless of the indication, PGD presents with an overarching controversy regarding the
destruction of embryos. After completing the IVF and PGD process, the remaining embryos
may be discarded, frozen for future use, or donated to either research or other couples
undergoing IVF (Cooper & Jungheim, 2010). A study conducted by Johns Hopkins Institutional
Review Board in April 2004 addressed the ethical issue regarding the point during PGD testing
at which the embryo is considered to have “moral worth” (Hudson, 2006, pp. 1638-1645). The
survey found that 47% of 6,000 participants stated the point of “moral worth” occurred once the
embryo was implanted in the womb. Twenty-six percent stated that the dividing embryo was the
point of “moral worth” (Hudson, 2006, pp. 1638-1645). The definition of moral worth and
human life of the embryo, concerning the PGD process, continues to be a highly debated issue.
Defining these terms in the process of PGD is particularly difficult (Boyle & Savulescu,
2001; Cooper & Jungheim, 2010). Without a definitive definition of moral worth and human life
of the embryo throughout the PGD process, the use of embryos and the actions taken on the
remaining embryos after implantation remain a highly debated aspect of PGD (Boyle &
Savulescu, 2001; Cooper & Jungheim, 2010).
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Each of the possible indications for PGD evokes ethical considerations. The least
controversial use of PGD is screening for Mendelian disorders, which reduces the possibility of
the embryo having genetic defects. The embryo would not have the detrimental genetic defect
upon implantation and growth. Non-Mendelian uses and the destruction of embryos after PGD
create more controversy. As mentioned previously, the Non-Mendelian indications include:
human leukocyte antigen typing involving the development of embryos for the indication of
being a “savior sibling,” non-medical sex selection for the implications of gender selection by
couple preference, non-medical trait selection involving selection for traits to give the embryo an
advantage in life, and selection of embryos for disability and disease (“Nonmendelian disorder,”
2002). PGD presents a variety of future reproductive technology applications for Mendelian and
Non-Mendelian disorders, and the ethical controversies surrounding each application has yet to
be fully understood and discussed.
Regulation
Regulation of IVF, PGS, and PGD varies widely from country to country. Based on an
IVF Worldwide study (2017), no updated worldwide registry exists with the exact PGD and PGS
utilization rate (Weissman et al., 2017). The United States government has minimal regulation
or monitoring of the PGD process; however, it does monitor aspects of the PGD process through
the U.S. Department of Health and Human Services, Center for Disease Control and Prevention,
Food and Drug Administration (FDA), and the Center for Medicare and Medicaid Services
(Hudson, 2006, pp. 1638-1645). Of these organizations, the FDA provides regulation of drugs
and devices that are utilized in the IVF and PGD process. In addition, “regulation of human
tissues for transplantation, facility registration, screen of infectious diseases, record keeping, and
the proper handling and storage of tissues” (Hudson, 2006, pp. 1638-1645) is overseen. The
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other organizations provide a window of opportunity for the United States government to
oversee the processes and provide regulation, if indicated (Hudson, 2006, pp. 1638-1645).
At the state level, each state can regulate the IVF and PGD processes, but few states have
implemented laws of this type. Some states have taken a stance on restricting embryos for
“research purposes” (Hudson, 2006, pp. 1638-1645). Louisiana prohibits the “intentional
destruction of embryos created through IVF” (Hudson, 2006, pp. 1638-1645). Many states have
yet to address the regulation of PGD processes, and as a result, there is a lack of understanding of
PGD from the general public and healthcare professionals of when and how PGD can be utilized
(Hudson, 2006).
Worldwide Perspectives and Prevalence of Preimplantation Genetic Diagnosis
A recent web-based survey called, “Preimplantation Genetic Screening (PGS): What is
My Opinion?,” was conducted in 2015 by IVF Worldwide, which discussed the progression and
views of PGS (Weissman et al., 2017). The study evaluated the usage patterns of PGS
worldwide to reveal common views and opinions on the topic within the assisted reproductive
technology community (Weissman et al., 2017). A web-based survey was sent out to IVF
clinical staff across the world, including both user and non-users of PGD, via the website IVFworldwide.com. The survey prompted results from 386 IVF clinics from 70 different countries
and is noted to have one of the highest response rates ever published by IVF-worldwide
(Weissman et al., 2017).
According to Weissman et al. (2017), the IVF Worldwide distributed a survey in 2015,
which collected data from 386 clinics throughout the world from those who have utilized PGS
and non-PGS users who were also IVF Worldwide members. The results showed that 342,600
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IVF cycles were performed on a yearly basis and 77% of the responding clinics routinely carried
out PGS. Results revealed the top three indications for PGS were maternal age >35 years,
patients with a history of repeated implantation failure, and patients who had recurrent pregnancy
loss and normal parental karyotype (Weissman et al., 2017). PGS was offered to all patients in
only 6% of the clinics (Weissman et al., 2017). Of the clinics that used PGS, PGS was
performed in less than 10% of IVF cycles in 47% of those clinics and was used in only 7% of
cycles in over 50% of those clinics (Weissman et al., 2017). A portion of respondents stated
PGS was not used in their countries due to a lack of technical skill and staffing, low patient
demand, cost, or because it was illegal in their country (Weissman et al., 2017). The study
analyzed what respondents believed PGS is capable of analyzing/detecting. Seventy-eight
percent of respondents believed that PGS can only prevent the transfer of aneuploid embryos,
72% believed it can reduce miscarriage rates, and 60% believed PGS can increase live birth rates
(Weissman et al. 2017). Results of this survey emphasize increased interest among the assisted
reproductive community for the usage of PGS. Furthermore, the results compiled from 70
countries suggested that physicians and researchers worldwide should share similar guidelines
on, and practices of, PGS as no regional specific response correlations revealed (Weissman et al.
2017).
Quinn et al. (2011) conducted a meta-analysis of perceptions of PGD worldwide. The
objective of the review was to assess high risk individuals’ knowledge and attitudes towards
PGD for hereditary cancer. High risk individuals were defined as individuals carrying gene
mutations at risk for passing on genetic cancer risk to their offspring (Quinn et al., 2011). A total
of 13 studies, published in English from high resource countries worldwide, were combined and
analyzed with 4,692 participants involved (Quinn et al., 2011). Overall the results indicated that
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35% had no knowledge of PGD and 71% thought PGD should be offered to those affected by
considerable risk for hereditary cancers. Of the participants, 50% would personally use PGD if
considerable risk for hereditary cancer was a concern. In regard to utilizing PGD to avoid a
pregnancy termination, 30% stated PGD should not be utilized. Finally, 33% acknowledged
ethical concerns of the PGD process (Quinn et al., 2011). Through this meta-analysis study, the
lack of knowledge about PGD, implications for use, and elimination of hereditary diseases is
evident, as approximately one third of participants had no knowledge of PGD (Quinn et al.,
2011).
United States’ Public Perspectives of Preimplantation Genetic Diagnosis
A nationwide study called “Public Awareness and Attitudes about Genetic Technology”
was conducted in 2002 by The Genetics and Public Policy Center at John Hopkins University.
At that time, most Americans approved of using genetic technology for medical purposes but
disapproved its use for non-medical sex selection or to select from desirable traits such as
intelligence or attractiveness (Princeton Survey Research Associates, 2002). Most people had
heard of genetic technologies, but only 24% had heard about PGD (Princeton Survey Research
Associates, 2002). This study further revealed that 74% of people approved of PGD to avoid
serious genetic disease, 69% approved to ensure the child is a blood match, 60% approved to
avoid predisposition diseases such as cancer, 28% approved to choose a child’s sex, and 22%
approved to select for desirable characteristics of the child (Princeton Survey Research
Associates, 2002). Furthermore, 72% approved of IVF, 66% approved of prenatal testing for
disease, and 59% approved of genetic engineering to avoid disease (Princeton Survey Research
Associates, 2002).
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As technology advances within the PGD process, opinions revolving around PGD arise.
A 2013 survey, conducted by Harris Interactive Service Bureau (HISB), inspected the US
general population’s perspectives on PGD. Participants were between the ages of 18 and 75
years old. The HISB cross-sectional study sought to quantify the viewpoints of the public, by
surveying a representative population, in respect to age, gender, socioeconomic status, education,
race, ethnicity, and religion (Winkelman et al., 2015). Of the 1,006 participants who responded
to the survey (94% response rate), motivations for favoring or opposing PGD varied. The
majority favored PGD (Winkelman et al., 2015). Support for PGD peaked with considerations
toward reducing fatalities early in life (72.9%) and eliminating lifelong disabilities, such as
mental retardation or deafness (66.7%) (Winkelman et al., 2015). The most common reasons for
favoring PGD included: couples should have reproductive autonomy (75.1 %), “couples should
be able to make their own decisions about having a child” (66.2%), and “PGD improves the
chances that a couple will have a healthy child” (62.1%) (Winkelman et al., 2015, pp. 665–675).
The most common reasons for opposing PGD were: “PGD interferes with nature and places
doctors in the role of playing God” (67.7%), “Widespread use of PGD may lead to unforeseen
consequences” (46.5%), “PGD leads to the unnecessary destruction of embryos” (45.8 %), “PGD
promotes discrimination against people with certain characteristics” (42.3 %), and “There is no
regulation of PGD” (22.3%) (Winkelman et al., 2015, pp. 665–675). Participants were more
supportive of PGD if they had knowledge of PGD prior to taking the survey (Winkelman et al.,
2015). When considering “diseases that may not occur until later in life, such as diseases that
place an individual at a high risk for cancer during adulthood,” 48% supported screening
(Winkelman et al., 2015, pp. 665-675).
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With regards to genetically-based trait selection, where does the public draw the line?
Favored sex selection was supported by 21% of participants; favored personality traits was
supported by 18.9%; favored physical traits were supported by 14.6% of participants
(Winkelman et al., 2015). Men were two to three times more supportive of genetically-based
trait selection (Winkelman et al., 2015). Winkelman et al. noted, “More research is needed to
further understand the different perspectives of men and women in regard to PGD and offspring
trait preferences” (2015, pp. 665–675).
As a whole, the 2013 study revealed significant variations in opinion based on gender,
race, and education (Winkelman et al., 2015). Asians were four times more likely to support
favored sex selection, and African Americans were two times more likely to support sex
selection, as compared to Caucasians (Winkelman et al., 2015). Participants with three or more
children were significantly less supportive of PGD for genetic diseases (Winkelman et al., 2015).
As of 2013, over 80% of United States fertility clinics allowed sex selection (Winkelman et al.,
2015). Demographically, 49.5% of participants knew someone with a developmental disorder,
27.7% knew about PGD before taking the survey, and 28.5% of participants knew someone who
used assisted reproductive technology to have a healthy pregnancy (Winkelman et al., 2015). In
general, participants supported limited applications, despite the widespread availability of
genetic screening and sex selection (Winkelman et al., 2015).
Physicians’ Perspectives of Preimplantation Genetic Diagnosis
A study conducted in 2012 surveyed 220 US internists on their views of the possibility of
treating genetic disorders by PGD (Klitzman et al., 2013). The survey in this study asked
questions about what diseases warranted PGD (Klitzman et al., 2013). Diseases included
hereditary ovarian/breast cancer, cystic fibrosis, Huntington’s disease, irritable bowel syndrome,
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Duchenne muscular dystrophy, familial retinoblastoma, adenomatous polyposis, and
cardiomyopathy, type I diabetes, among others (Klitzman et al., 2013). Results found that many
providers would recommend PGD to patients for cystic fibrosis (33.7%), breast cancer (BRCA
23.5%), familial adenomatous polyposis (FAP 20.6%), and familial hypertrophic
cardiomyopathy (19.9%). Far fewer were in support of social sex selection (5.2%) (Klitzman et
al., 2013). Over 50% were unsure if they would recommend PGD in every disease asked about
(Klitzman et al., 2013). Of those surveyed, only 4.9% had suggested PGD to patients and only
7.1% felt they could adequately answer patients’ questions regarding the topic (Klitzman et al.,
2013).
Approximately half (49.4%) would not recommend PGD to patients for sex selection due
to non-medical reasons, and 45.4% were unsure (Klitzman et al., 2013). The study suggests that
internists feel they have insufficient knowledge about PGD and many are unsure when to discuss
the option with patients, even with genetic disorders such as cystic fibrosis and Duchenne
muscular dystrophy, which are more commonly utilizing PGD for detection (Klitzman et al.,
2013). For example, 54.3% of internists were uncertain about referring in cases of cystic
fibrosis, 56.9% of internists were uncertain about referring in cases of Huntington’s disease,
54.9% of internists were uncertain about referring in cases of Duchenne muscular dystrophy.
Other diseases and indications discussed with internists include: familial retinoblastoma, familial
adenomatous polyposis, familial hypertrophic cardiomyopathy, hereditary breast/ovarian cancer,
long QT syndrome, Type I diabetes, inflammatory bowel disease, and sex selection without
medical implications, of which internists were uncertain when to refer in 50-60% of cases
(Klitzman et al., 2013). This study shines light on the fact that physicians, specifically internists,
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need more education and training to fully understand PGD in order to make informed
recommendations, referrals, and decisions for PGD testing.
In 2003, a set of qualitative interviews with genetic professionals, pediatricians, and
parents in Chicago, Illinois were conducted to evaluate perspectives on genetic testing (Campbell
& Ross, 2004). The study focused on evaluating the benefits and risks of predictive genetic
screening of young children for genetic links to criminal behavior (Campbell & Ross, 2004).
Healthcare professionals largely opposed genetic testing unless treatment was available, and,
consequently, opposed genetic screening of young children for genetic links to criminal behavior
(Campbell & Ross, 2004). Parents, on the other hand, supported the use of genetic testing even
in the absence of treatment, like testing for genetic links to criminal behavior (Campbell & Ross,
2004). Parents focused on environmental influences and changes (Campbell & Ross, 2004).
Pediatricians and genetic professionals were concerned with potential harm of parents and
children possessing the negative information, which could lead to environmental changes or selffulfilling prophecies (Campbell & Ross, 2004).
From a United States 2014 survey, attitudes of 163 neurologists and 372 psychiatrists
were evaluated (Abbate et al., 2014). Of the respondents, approximately 25% of neurologists
and 32% of psychiatrists discussed genetic testing with their patients; however, only 2.9%
neurologists or psychiatrists discussed PGD (Abbate et al., 2014). Most psychiatrists and
neurologists would refer patients for PGD who were at risk for passing on Huntington's disease,
Tay-Sachs, and cystic fibrosis (CF). Specifically, 69.8% of psychiatrists and 59.3% of
neurologists would refer patients for PGD for CF (Abbate et al., 2014). For Huntington’s
disease, 74.7% of psychiatrists and 59.3% of neurologists would refer for PGD (Abbate et al.,
2014). Only 11.5% of psychiatrists and 7.6% of neurologists would refer for sex selection
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(Abbate et al., 2014). Paralleling the internist study, the majority of providers did not feel
knowledgeable for patient referrals or answering questions about PGD due to limited experience
with PGD and genetic testing (Abbate et al., 2014).
In a United States 2010 study, only 17% obstetricians/gynecologists respondents felt that
they were knowledgeable about PGD (Abbate et al., 2014). When asked what six cancer
syndromes (cancer syndromes associated with genetic mutations) can be detected with PGD,
only 22% answered correctly (Abbate et al., 2014). Additionally, 43% of
obstetricians/gynecologists referred patients with hereditary cancer for PGD (Abbate et al.,
2014).
The idea that providers have a lack of knowledge on PGD was supported in a study done
in 2016 in Malaysia (Olesen et al., 2016). The study analyzed the perspectives of medical
professionals regarding ethical implications and issues pertaining to PGD by interviewing
medical professionals working with women or couples in the process of undergoing PGD
(Olesen et al., 2016). Through extensive interviewing, the study revealed that ‘low health
literacy’ of patients, described as lack of information and limitations about PGD, contributed to
misconceptions, total rejections, and negative attitudes towards PGD and patients who choose to
use it (Olesen et al., 2016, para. 1). These findings are consistent with past studies done
indicating that “low knowledge of PGD leads to a moderate acceptance of PGD and to a high
level of need for information about PGD” (Olesen et al., 2016, para. 20).
Conclusion
As technology continues to advance, ethical concerns have inevitably attracted the
attention of those favoring and opposing PGD. Consequently, researchers globally have
attempted to quantify the opinions and rationale surrounding PGD to gather a consensus. Amidst
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the plethora of data points presented in this literature review, a single conclusion emerges: no
consensus exists. Generally, research has shown that medical experts are in support of PGD for
the medical purposes of avoiding serious and life-threatening genetic diseases but are not as
supportive in using PGD for less serious or late onset diseases or sex selection (Olesen et al.,
2016). Populations frequently studied were the public and specialty health care providers.
However, no studies were found regarding the perspectives on PGD with regards to PAs. The
goal of this study is to analyze PAs’ approval and disapproval rate of PGD use for Mendelian vs.
Non-Mendelian disorders and the common reasons of approval and disapproval of the utilization
of PGD, with respect to the Central US and West Coast.
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Chapter 3: Methodology
Introduction
The purpose of this study was to determine the percentage of PAs that approve and
disapprove of PGD use for Mendelian vs. Non-Mendelian disorders along with the common
reasons that PAs approve and disapprove of the utilization of PGD. This study attempted to
evaluate the following questions:
1. What is the percentage of PAs that approve of PGD use for Mendelian vs. NonMendelian disorders?
2. What is the percentage of PAs that disapprove of PGD use for Mendelian vs. NonMendelian disorders?
3. What are the most common reasons PAs approve the use of PGD?
4. What are the most common reasons PAs disapprove the use of PGD?
The following sections will outline the methodology and the population of the study. The
study design, instrumentation technique, population description, study procedure, data collection
and analysis, study validity and reliability, as well as study delimitations and limitations will be
described below.
Study Design
The research was a quantitative study surveying PAs from two different regions within
the United States (US), including the Central US and the West Coast. Based on the practicing
PA population within each respective region, members of California Academy of Physician
Assistants [CAPA (CA)] (>2,801 practicing PAs) and members of Kansas Academy of Physician
Assistants [KAPA (KS)] (602-1275 practicing PAs) were surveyed. A survey was used to
collect PA perspectives, understandings, and ethical considerations of PGD. As a web-based
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survey tool, an email was sent to certified PA members through each states’ respective Academy
for Physician Assistants with a link to the survey included. A statement of confidentiality and
informed consent was included at the beginning of the survey, and no contact or personal
information was collected. The survey was open to complete from July 10, 2018 to September 1,
2018. A reminder email was sent to CAPA and KAPA organizations, who then sent a
subsequent email to the respective members, every three weeks to improve response rates.
Materials and Instrumentation
The research study used a twelve-question survey, modified from a study conducted by
Winkelman et. al, which analyzed the public’s perspectives on the use of PGD (2015).
Permission was obtained from William Winkelman MD, by telephone and confirmed via email
(Appendix A) to use and make appropriate changes to the previous survey (Appendix B).
Alterations were made to the background information about PGD, due to surveying certified PAs
rather than the general public. Additionally, throughout the survey questions the term ‘doctor’
was substituted with ‘provider’. When considering the target population of PAs, non-pertinent
demographic questions were excluded. The only demographic question included asked
participants for the state in which they practice as a PA. See adapted survey tool in Appendix C.
The first three questions of the survey asked about participants’ beliefs regarding PGD
use to screen embryos for certain medical conditions or diseases which could be life threatening
or cause disability, otherwise considered Mendelian Disorders. Options for answers to the
questions were strongly disagree, disagree, neither agree nor disagree, agree, and strongly agree.
Questions four and five asked participants to select any or all options that pertain to why a
participant may agree or disagree with the use of PGD in particular scenarios.
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The following section included four questions designed to explore participants’ beliefs
regarding whether PGD should be used to screen embryos for gender selection, physical
characteristics, personality traits, or sexuality, otherwise considered Non-Mendelian traits. The
options for answers to the questions were strongly disagree, disagree, neither agree nor disagree,
agree, and strongly agree. The next question referenced the previous questions’ responses. If the
participant agreed to the prior questions for the use of PGD to screen embryos for gender
selection, physical characteristics, personality traits, or sexuality, the participant was then
prompted to select any of the three responses listed pertaining to why they agreed. The
following question, if they disagreed to the prior questions, asked participants to select any that
apply of the five options listed for why they disagreed with the use of PGD.
Lastly, the survey included a demographic section which asked in which state the
participant practices.
The survey in this study was used to collect the following information:
1. Data conveying how many PAs approve the use of PGD for Mendelian disorders.
2. Data conveying reasons why PAs approve the use of PGD for Mendelian disorders.
3. Data conveying how many PAs disapprove the use of PGD for selecting for NonMendelian traits.
4. Data conveying reasons why PAs disapprove the use of PGD for selecting for NonMendelian traits.
Study Population
In order to obtain a large population and formulate generalized statements of the US
population in regards to PGD, the study utilized the responses of PAs from one state of the
Central US and West Coast regions. The state from each of these regions was chosen from data
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collected by the National Commission on Certification of Physician Assistants (NCCPA) in
2016. The data indicated which states within the US had the highest PA population. From this
data, California and Kansas, with more than 2,801 practicing PAs in each state, were chosen
from the respective regions out of convenience and an attempt to obtain the largest sample size
possible.
Responses were obtained from willing participants ages 18 - 75, who were PAs and
members of the CAPA and KAPA. Obtaining the responses from PAs of a variety of health
systems and specialties was intended to reduce any bias in the data collection. Consent was
obtained through email from CAPA’s and KAPA’s administrators after the executive board
approval (Appendix D).
The survey was distributed from July 10, 2018 to September 1, 2018. All survey
participants were required to read an informed consent prior to taking the survey. To be included
in the study, the participants need to speak English fluently as the survey was created and
intended for fluent English participants and no adjustment was in place for non-fluent Englishspeaking individuals. Additionally, the participants needed to be 18 years of age or older, as
parental consent would have been needed for anyone under the age of 18. Demographic
information obtained only included state of membership. No personal identifier information was
obtained from the participants.
Procedure
Consent to utilize the survey was obtained through email prior to sending out the webbased survey to the specific state PA associations. William Winkelman, MD gave consent to
utilize, alter, and distribute his survey tool (Appendix A). Alterations to the survey tool were
reviewed by research chair, Christina Hanson, PA-C. Additionally, an email was sent to CAPA
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and KAPA requesting permission to survey their members to quantify PA perspectives on PGD.
Access to CAPA members was requested and granted through Jonathan Kulesza (Appendix D).
Access to KAPA members was requested and granted through Douglas Smith (Appendix D).
Initially, the survey tool (Appendix C), was emailed to each respective representative from
CAPA and KAPA (Appendix D). Secondly, each representative distributed the survey, by email,
to their respective Academy of Physician Assistant members. Reminder emails were distributed
to Douglas Smith, KAPA representative, and Jonathan Kulesza, CAPA representative, every
three weeks until the conclusion of the study (Appendix D). Data was collected using Qualtrics,
a web-based research software program, and surveys were initiated with a hyperlink.
Participants were presented a statement of confidentiality, informed consent, and a brief
explanation of the study’s purpose (Appendix E). No contact or personal information was
obtained. Data collection from the survey spanned from July 10, 2018 to September 1, 2018.
Access to the survey was closed from further participants on September 1, 2018. Data was
downloaded on an encrypted, single USB, deleted from Qualtrics server, and stored in a locked,
research office at Bethel University Anderson Center, Arden Hills, Minnesota. Raw data,
processes, and statistical analysis was stored on the USB. Throughout research analysis,
responses were temporarily stored on a password protected computer. Once data analysis was
uploaded onto a USB, all survey data and analysis was deleted from the password-protected
computer. The encrypted, single USB will be kept for five years, and then destroyed.
Statistical Analysis
Data collected from the survey through Qualtrics was downloaded and analyzed. First,
the frequency of participants’ responses for each question was quantified. Using the Likert scale
options for answers to the survey questions, the number of participants that strongly agree, agree,
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neither agree nor disagree, disagree, or strongly disagree for each question was quantified. Then
using the frequencies, researchers determined the percentage of participants that answered each
response of each question. This revealed the percentage of PAs that approve or disapprove of
the use of PGD for Mendelian disorders (questions 1-3) and Non-Mendelian traits (questions 69). Regarding questions 4, 5, 10, and 11, the responses for the common reason(s) of approval or
disapproval of the use of PGD were also quantified and calculated into percentages for
representation.
Next, MedCalc statistical software comparison of proportions calculator was used to
determine statistical significance for comparing the frequency of approval vs. disapproval
responses for each question. For these calculations in each question, strongly agree and agree
responses were grouped together and strongly disagree and disagree responses were grouped
together. The two groups were then compared to find p-values for each question and whether
there was a difference between approval and disapproval of PGD in each medical scenario.
Furthermore, because the responses to questions 1-3 were quite varied, a repeat ANOVA
test was done to compare the three questions to determine if participants preferred approval or
disapproval of PGD use for a specific Mendelian condition. The repeat test was used to compare
the three questions because each participant was asked the same three questions. Responses
were scored as the following: strongly agree=5, agree=4, neither agree nor disagree=3,
disagree=2, strongly disagree=1. The repeated ANOVA test was done to determine the p-values
for comparing each question to another (Table 1).
Physician assistants’ perspectives of PGD use, quantified from the survey question
results as described above, were then compared to the results of the original Winkelman, et al
(2015) survey regarding public perspectives on the use of PGD. The comparison between the
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general public perspectives on PGD to that of PAs revealed if there are quantitative differences
between the two groups.
Validity and Reliability
The researchers performing this study adapted the survey for the use of analyzing the
responses from PAs. The original survey tool was formulated by a study conducted by William
Winkelman, MD, who specifically had the survey tool catered to surveying physicians’ and the
general public’s understandings, perspectives, and ethical considerations of PGD. The original
survey was completed by 1,006 participants who were members of the Harris Interactive Service
Bureau (HISB). The respondents were selected to participate to provide representation based on
sex, education, race/ethnicity, geography, religion, and income. Additionally, the participants of
the survey had to be U.S. residents aged 18 - 75 years. The original study was approved by the
Human Research Committee of Brigham and Women’s Hospital prior to distribution.
Utilizing the questions of a previously published study in a peer reviewed journal,
completed by 1,006 participants, added to the validity and reliability of this study’s survey.
Validity of the survey tool was ensured from the review by the Human Research Committee of
Brigham and Women’s Hospital prior to distribution, providing basic information of PGD to
participants prior to completing the survey, and limiting the responses available to the
participants. Reliability was also ensured by all participants completing the exact same survey,
thus, all participants received the same background information about PGD and read and
completed the exact same survey questions.
The adapted survey included basic information about PGD, thus all the participants had a
basic understanding prior to completing the survey. Validity was confirmed when asking
questions relevant to the understandings, ethical considerations, and perspectives about PGD,
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which had been previously utilized in Dr. William Winkelman’s survey tool. After each
question, the participant had four to five response options depending on the question. The
reliability of the study was determined by making the survey questions precise and consistent by
having “strongly agree/agree/neither agree nor disagree/disagree/strongly disagree” for many of
the responses. Thus, the responses of the survey were those of the participant and specifically
the participant’s opinion about PGD.
The same survey was utilized when collecting the responses from all participants, which
ensured the study is reliable throughout the study population. Lastly, the survey tool was
reviewed by an expert panel consisting of four Minnesota practicing PAs, reviewing the survey
tool for relevance and validity to the intended population.
Limitations and Delimitations
The survey in this study was sent out to members of CAPA and KAPA. The response
rate was dictated by recipients’ decision to either participate or not participate. The willingness
to participate in this survey may have been influenced by recipients’ previous knowledge or
interest about the topic. Variables such as exposure to PGD, religious environment, and cultural
environment varying by region may have influenced trends in perspectives. Due to the
controversial nature of PGD, the resultant data may have been skewed by subsequent response
bias by those who choose to participate. The participants may have been influenced by societal
pressures or expectant responses and answered questions misleadingly or untruthfully. Not all
practicing PAs in California or Kansas are members of their respective Academy, which lowered
the number of PAs who received the survey, thus lowering the potential response rate. CAPA
had a 50% membership of practicing PAs within the state. KAPA had a 13% membership of
practicing PAs within the state.
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Additionally, using CAPA and KAPA as a distributor of the survey may have limited the
comprehensiveness of the research, as not all PAs practicing in these states are members of
CAPA and KAPA. The survey only reached a portion of PAs in the states where the survey was
distributed, therefore, results do not encompass all PAs across the entire US. Another limitation
of utilizing CAPA and KAPA is that the researchers were not able to randomize the participants
of the survey. Subsequently, the participants were compiled of those who chose to participate
only and were members of their respective academy.
Notable de-limitations imposed by the researchers include selection bias based on the
regions where the survey was distributed. For the purpose of this study, CAPA and KAPA were
utilized to distribute the survey to one state in each the Central US and West Coast regions. The
selection of two states was due to three reasons: striving to survey states with the highest PA
population in the Central US and West Coast regions according to NCCPA 2016 data, the
impractical and limited nature of obtaining information from PAs from every US state, and
striving to obtain a broad view of the approval and disapproval rates of PGD use for Mendelian
vs. Non-Mendelian disorders/the common reasons of approval and disapproval of PGD use of
PAs across the US. Only two states were selected to survey, which limited the sample size
allowing for a manageable data set for analysis.
Utilizing a survey for the basis of the research is another de-limitation imposed by the
researchers. Respondents answers may have been influenced by survey format, wording of
questions, or answer options, thus influencing survey results.
Conclusion
The research methodology involved emailing a survey to members of CAPA and KAPA
to collect data about the percentage of PAs that approve and disapprove of PGD use for
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Mendelian vs. Non-Mendelian disorders and the common reasons that PAs approve and
disapprove of the utilization of PGD. The results of the survey are relevant due to the increase in
practicing PAs and an increase in PGD utilization in reproductive technology. As PGD becomes
more prevalent in reproductive technology, assessing PAs’ approval and disapproval rates of
PGD use for Mendelian vs. Non-Mendelian disorders and the common reasons of approval and
disapproval of PGD becomes crucial in providing optimal care to patients. Chapter 4 will
analyze the results of the surveys by quantifying responses to the survey questions. Chapter 5
will contain research limitations and analysis of conclusions made from the quantitative results.
Lastly, Chapter 5 will include discussion for possibilities of future research.
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Chapter 4: Results
Data collection occurred from July 10, 2018 until September 1, 2018, yielding a response
of 15 respondents. Survey was open to Kansas Academy of Physician Assistants and California
Academy of Physician Assistants. Fifteen total participants started the electronic survey, with 14
participants completing the survey. All 14 participants completing the survey were from KAPA.
No responses were obtained from CAPA.
After downloading data responses from Qualtrics, all eleven questions were evaluated
with respect to PGD perceptions, understandings, and ethical considerations. Frequency of
responses were obtained and raw percentages were calculated. Comparisons were made between
strongly agree/agree groups vs strongly disagree/disagree groups for each question 1-3 and 6-9.
Comparisons were also made between responses to Mendelian condition questions 1-3.
First, the grounds on which PGD should or should not be performed by providers were
quantified for Mendelian conditions, with respect to: diseases fatal early in life, diseases that
cause lifelong disability such as mental retardation or deafness, and diseases that may not occur
until later in life, such as diseases that place an individual at a high risk of cancer during
adulthood (Figure 1).
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Figure 1. Percentage of KAPA Physician Assistants who strongly agreed, agreed, neither agreed
nor disagreed, disagreed, and strongly disagreed PGD should be used for Mendelian conditions:
diseases fatal in the first few years of life, diseases that cause lifelong disability such as mental
retardation or deafness, and diseases that may not occur until later in life, such as diseases that
place an individual at a high risk of cancer during adulthood (n=14).
Perspectives from KAPA Physician Assistants were mixed. When screening for diseases
fatal early in life, 50% of participants agreed or strongly agreed with the use of PGD, 43%
disagreed or strongly disagreed, and 7% neither agreed nor disagreed to the use of PGD. There
was no statistical significance for agree/strongly agree vs disagree/strongly disagree groups
(p=0.72). When screening for diseases that cause lifelong disability such as mental retardation or
deafness, 43% of participants agreed or strongly agreed in the use of PGD, 43% disagreed or
strongly disagreed, and 14% neither agreed nor disagreed. Finally, when screening for diseases
that may not occur until later in life, such as diseases that place an individual at a high risk of
cancer during adulthood, 29% of participants agreed or strongly agreed with the use of PGD,
43% of participants disagreed or strongly disagreed, and 29% neither agreed nor disagreed in the
use of PGD. There was no statistical significance between agree/strongly agree vs
disagree/strongly disagree groups (p=0.45).
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Those who agreed or strongly agreed to using PGD for screening did so most often on the
grounds of: PGD improving the chances that a couple will have a healthy child (43%, n=7) and
that couples should be able to make their own decisions about having a child (57%). One
participant did so on the grounds that PGD can eliminate certain genetic diseases forever (14%).
Those who disagreed or strongly disagreed to using PGD for screening did so most often on the
grounds of: PGD interfering with nature and places providers in the role of “Playing God” (71%,
n=7), and PGD promoting discrimination against people with certain diseases (29%).
Next, because the responses to questions 1-3 were quite varied, responses of these
questions were scored and compared to determine if participants preferred approval or
disapproval for the use of PGD for any of the following situations: 1) diseases fatal in the first
few years of life, 2) diseases that cause lifelong disability such as mental retardation or deafness,
and 3) diseases that may not occur until later in life, such as diseases that place an individual at a
high risk of cancer during adulthood. Analysis showed no statistical significance between the
three situations (see Table 1 p-values for each comparison situation). All p-values were >0.05.
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Table 1
Pairwise Comparisons for Responses to Mendelian Conditions Regarding PGD approval or
disapproval

Mendelian conditions compared for the use of
PGD
Diseases fatal in the
first few years of life

Diseases that occur
later in life

Diseases the cause
lifelong disability

P

a

95% CI

a

Mean
difference

Std.
Error

0.5

0.203

0.0855

-0.0574 to
1.057

-

later in life

-

lifelong disability

0.214

0.114

0.2468

-0.0982 to
0.527

-

1st few years of
life

-0.5

0.203

0.0855

-1.057 to
0.0574

-

lifelong disability

-0.286

0.163

0.3116

-0.734 to 0.163

-

1st few years of
life

-0.214

0.114

0.2468

-0.527 to
0.0982

-

later in life

0.286

0.163

0.3116

-0.163 to 0.734

Results of a repeated ANOVA test to compare the responses to questions 1, 2, and 3. Data was
scored as the following: strongly agree=5, agree=4, neither agree nor disagree=3, disagree=2,
strongly disagree=1. P-values reveal no statistical significance when comparing approval rates
for Mendelian conditions.
Second, the grounds on which PGD should or should not be performed by providers were
quantified for Non-Mendelian traits, with respect to: sex selection, physical characteristics such
as height, eye color, or athleticism, personality traits such as intelligence or aggression, and for
sexual orientation such as homosexuality (Figure 2).
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Figure 2. Percentage of KAPA Physician Assistants who strongly agreed, agreed, neither agreed
nor disagreed, disagreed, and strongly disagreed PGD should be used for Non-Mendelian traits:
sex selection, physical characteristics such as height, eye color, or athleticism, personality traits
such as intelligence or aggression, and for sexual orientation such as homosexuality (n=14).
With regards to sex selection, 93% of participants disagreed or strongly disagreed to the
use of PGD. Likewise, with regards to screening for physical characteristics such as height, eye
color, or athleticism, 93% of participants disagreed or strongly disagreed to the use of PGD.
When considering screening for personality traits such as intelligence or aggression, 86% of
participants disagreed or strongly disagreed to the use of PGD. The majority of participants
(86%) strongly disagreed to screening for sexual orientation such as homosexuality with PGD,
with two participants who disagreed to the use of PGD (14%). When comparing strongly
agree/agree vs strongly disagree/disagree groups in each of the four questions, there is a
statistically significant difference for each question p<0.0001, considering there were zero
participants who agreed or strongly agreed for all questions.
Those who neither agreed nor disagreed to the use of PGD for sex selection, physical
characteristics, personality traits, and for sexual orientation did so on the grounds that couples

54

should be able to make their own decisions about having a child (100%, n=2). Those who
disagreed or strongly disagreed to the use of PGD for sex selection, physical characteristics,
personality traits, and for sexual orientation did so on the grounds most often because PGD
promotes discrimination against people with certain characteristics (46%, n=13). Other
considerations included: PGD interferes with nature and places providers in the role of “playing
God” (31%), widespread use of PGD may lead to unforeseen consequences (15%), and PGD
leads to unnecessary destruction of embryos (8%).
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Chapter 5: Discussion
Summary of Results
The purpose of this study was to analyze the PA approval and disapproval of the use of
PGD based on the survey results. Due to the survey response rate of 14, of which were all from
KAPA, results were inconclusive. Through statistical analysis, it was determined that in order to
potentially detect a statistical significance in data, power of detection would need to be increased
to 80%, and in order to do so, sample size would need to be between 32-45 participants. One
conclusion that can be drawn, is the fact that perspectives on PGD utilization amongst KAPA
members who responded to the online survey are varied.
When looking at the data, even despite the low response rate, subtle trends may exist. No
conclusive indication of whether PGD should be utilized for Mendelian conditions was detected.
Regarding opinions on PGD use for diseases in the first few years of life, the results were split
almost fifty-fifty, with 50% of participants agreeing/strongly agreeing, 43% disagreeing/strongly
disagreeing, and 7% who neither agreed nor disagreed to the use of PGD. This discourse
continues for subsequent topics as well. Responses for screening for diseases that cause lifelong
disability such as mental retardation or deafness were also split, with 43% of participants
agreeing/strongly agreeing in the use of PGD while 43% disagreed or strongly disagreed.
Screening for diseases that may not occur until later in life also yielded mixed results, with 29%
of participants agreeing/strongly agreeing in the use of PGD and 43% of participants
disagreeing/strongly disagreeing in the use of PGD.
The common reasons KAPA members approved of the use of PGD did so on the grounds
of PGD improving the chance of the couple having a healthy child, and that the couple should be
able to make their own medical decisions about having a child. A further explanation for these

56

common reasons chosen is as follows. When looking at the options available in the reproductive
realm, utilizing PGD to improve the chance of having a healthy child and being able to make
these decisions independently is becoming increasingly common. From a medical standpoint,
the patient has the choice to complete testing and procedures. The PGD process is a laboratory
test completed on DNA of an embryo. Therefore, the choice to complete PGD testing should be
up to the couple, and the couple should be able to make their own medical decisions about
having that child.
The common reasons KAPA members disapproved of the use of PGD for Mendelian
conditions were due to believing PGD interferes with nature and placing providers in the role of
“playing God.” These commonly cited reasons of PGD use disapproval is not particularly
surprising, as they address core, controversial ethical considerations surrounding PGD. The use
of PGD can be viewed as “playing God,” as the doctors are analyzing the embryos to choose the
embryo without particular diseases or conditions. Utilizing the PGD process may eliminate
certain diseases that could lead to death or detrimental conditions. Utilizing PGD may also be
perceived as manipulating genetics in an omniscient, authoritative manner. Another viewpoint
of utilizing PGD can be viewed as eliminating certain communities such as the deaf community.
On the second half of the survey, a shift in responses occurred. When considering PGD
for more exclusively non-Mendelian genetic traits, such as sex selection, physical characteristics
such as height, eye color, or athleticism, personality traits such as intelligence or aggression, and
for sexual orientation such as homosexuality, participants predominantly disagreed with PGD
use. No participants agreed or strongly agreed in the use of PGD for sex selection, physical
characteristics, personality traits, and for sexual orientation. The majority of participants
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disagreed or strongly disagreed with the use of PGD under such trait conditions, and only a
couple participants neither agreed nor disagreed.
One might argue a consensus within this survey was reached. However, the reasons
participants made the stance of disagreeing on the use of PGD for sex selection, physical
characteristics, personality traits, and sexual orientation were quite varied. For example, the
most commonly cited reason for disagreeing with PGD use was supported by less than half
(46%) of participants, doing so because PGD promotes discrimination against people with
certain characteristics. Other responses ranged from PGD interfering with nature and places
providers in the role of “playing God” (31%), widespread use of PGD may lead to unforeseen
consequences (15%), and PGD leads to unnecessary destruction of embryos (8%).
Regarding the direct comparison between this study and the 2013 study completed by
Dr. William Winkelman, significant conclusions cannot be drawn due to the lack of responses of
this study. Overall, the 2013 survey that analyzed the US general population’s perspectives on
PGD indicated that the majority favored PGD (Winkelman et al., 2015). Support for PGD
peaked with considerations toward reducing fatalities early in life (72.9%) and eliminating
lifelong disabilities, such as mental retardation or deafness (66.7%) (Winkelman et al., 2015).
This study had mixed responses on the support of PGD with roughly 50% of KAPA members
supporting PGD use for screening for diseases fatal early in life and screening for diseases that
cause lifelong disability such as mental retardation or deafness. The support for PGD use
dropped slightly to 29% when screening for diseases that may not occur until later in life.
Initially, it may appear that the general public and KAPA members support the use of PGD for
prevention of diseases, conditions such as mental retardation or deafness, or screening for
diseases that present later in life; however, roughly 40% of KAPA members disagreed with the
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use of PGD for screening early life diseases and conditions such as mental retardation or
deafness. In screening for diseases that present later in life, roughly 40% disagreed with the use
of PGD. In comparison, the general public tends to have a more supportive stance on the use of
PGD than the KAPA members surveyed in this study.
Common reasons KAPA members supported the use of PGD did so on the grounds of
PGD improving the chances that a couple will have a healthy child and that couples should be
able to make their own decisions about having a child. In the study completed by Dr. William
Winkelman, the most common reasons included: couples should have reproductive autonomy,
“couples should be able to make their own decisions about having a child”, and “PGD improves
the chances that a couple will have a healthy child” (Winkelman et al., 2015, pp. 665–675). The
KAPA members and the general public both have a high percentage agreeing with the use of
PGD for improving the chances of the couple having a healthy child, and the couple being able
to make their own decisions about having a child.
Those that disagreed with the use of PGD did so on the grounds that it would be
interfering with nature and be considered “playing God.” Similarly, the general public opposed
the use of PGD on the grounds that “PGD interferes with nature and places doctors in the role of
playing God.” In comparison with the use of PGD for analysis of physical characteristics and
sex selection, the majority of KAPA members did not support the use of PGD for such a process.
Similarly, the general public had a low percentage supporting the use of PGD for sex selection or
physical characteristics selection. When considering the study conducted by John Hopkins
Institutional Review Board in April 2004, it was found that 72% of 6,000 participants disapprove
of utilizing PGD testing for non-medically related traits (Hudson, 2006).
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Limitations and Delimitations
A limited number of PA academies were targeted for distribution of the study’s survey, a
factor imposed by the researchers. For the purpose of this study, academies from the East Coast,
Central US, and West Coast were chosen based on population of practicing PAs within the state.
Three state academies were chosen to collect data and make a generalized analysis of US PA
approval and disapproval of the use of PGD. Additionally, three state academies were chosen to
limit the data responses for analysis. California (CAPA), Kansas (KAPA), and Virginia (VAPA)
were chosen and agreed to participate in the study.
During the initial distribution of the survey, due to administrative changes, VAPA was no
longer able to distribute the survey for this study. As a result, the distribution of the survey was
further limited and generalized statements about the US PAs approval and disapproval of the use
of PGD cannot be made. CAPA and KAPA participated in the distribution of the survey,
therefore, data analysis and statements were anticipated to be made about the Central US and
West Coast. Zero CAPA members participated in the survey, therefore no analysis could be
done for the West Coast.
The use of the survey for this study did not encompass all possible reasons for PGD use
or all of the approval or disapproval reasons one might have. The survey was utilized as a tool to
further narrow the possible responses and data collected. The use of a web-based survey tool
limited the distribution to those practicing with the respective states and members of the
respective academies. The online survey also limited the distribution to those that regularly
check their Academy’s website or emails.
In addition to the limited distribution of the survey to CAPA and KAPA, the sample size
of participants was less than anticipated. The study received 15 responses with only 14
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participants completing the entire survey. Factors that may have influenced participation may
have been due to not all PAs being members of their states respective academies, the lack of face
to face contact between the researchers and survey participants, the method of delivery of the
survey to the PAs, and lastly, the individual distributing the survey to the PA members or the
participants themselves may have held a bias towards the topic being studied.
Face to face interaction may have increased the PA response to the survey, as the PAs
would have received the information about the survey and would have been able to complete the
survey in person. The lack of face to face contact may have influenced the response rate,
especially when considering each academy delivered the survey link and information differently.
Modality of survey distribution differed between CAPA and KAPA, with CAPA posting the
survey link on the CAPA website and KAPA emailing the link to their members. As a result, the
awareness about the survey, including ease of access to the survey, may have impacted the
response rate.
The controversial nature of PGD use may have influenced the distribution of the survey,
further impacting the response rate. The contact person for each academy may have influenced
the response rate to the survey by having a bias about the subject matter. In addition, CAPA and
KAPA members’ basic foundation of knowledge and personal discrepancies about PGD may
have influenced their motivation to participate in this study. Lastly, when completing the survey,
the responses of the participants may have been dishonest. When considering the various
confounding variables, the results, therefore, may not have accurately reflected PA’s approval or
disapproval of the use of PGD.
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Further Research
Investigating perspectives about PGD in the medical community addresses an important
topic. With regards to addressing PAs’ understanding and stance on indications for PGD use,
this study provided a sliver of insight into where KAPA members stand on the issue. Results of
the study showed vague generalizations in which participants tended to agree with the use of
PGD for Mendelian conditions such as genetic diseases, and tended to disagree with the use of
PGD for non-Mendelian genetic traits such as physical characteristics. When considering the
low survey response rate, there lies quite a bit of room for improvement in future research. As
advancements in genetics will continue to make strides forward, PGD is likely to become more
prevalent in practice. Thus, the topic of this study will be important to continue researching to
stay updated on providers’ perspectives of PGD. Knowing provider perspectives on PGD is
important for patient care and considering how providers may be discussing PGD with their
patients. Learning more about provider perspectives on PGD will also be helpful in analyzing
where providers would benefit from further education about PGD and genetic medicine in
general in order to educate their patients effectively.
The simplest, and perhaps most important factor to improve further research for this
study is to increase the sample size of the survey participants. A response rate of fourteen is
certainly not enough for statistical significance. While it offers a glimpse of current PA
perspectives on PGD use, a greater sample size would enable a more conclusive and nuanced
understanding on the population, as a whole. Future researchers could attempt to expand the
survey population by targeting PAs across the country in different ways, not simply through state
PA academies. For example, increasing the sample size could be done through using different
distribution techniques for the survey such as emailing or mailing the survey directly to PAs, or
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by using face to face contact with PAs to distribute and collect a hard copy of the survey.
Researchers could seek out PAs to complete the survey in their workplace or possibly at
conferences through the national or state PA associations.
Future research could further examine factors such as participants’ detailed background
demographics, prior knowledge of PGD, experience with PGD, if they have children, if they
know anyone with genetic disabilities, etc. and examine correlation with those factors and their
respective perspectives on PGD use. Additionally, future research could investigate how gender
plays a role into participants’ opinions towards PGD. For example, Winkelman’s study found
that men were two to three times more supportive of genetically-based trait selection
(Winkelman et al., 2015). Winkelman et al. noted, “More research is needed to further
understand the different perspectives of men and women in regard to PGD and offspring trait
preferences” (2015, pp. 665–675). The relationships between additional factors asked and
participants’ answers could open up avenues to learning about how one’s background and
personal life affects their perspectives towards the use of PGD in medical practice.
Additionally, future research could explore further into the reasons why PAs may agree
or disagree with the use of PGD. The survey in this study listed only three to four options to
choose from as to why the participant may agree or disagree with PGD under certain
circumstances, when in reality, reasoning behind such opinions could be abundant. Responses
varied greatly, making it difficult to draw conclusions. In the future, it could be interesting for
participants to answer open-ended questions in a qualitative setting to get a better idea of reasons
why PAs agree or disagree with PGD use.
Finally, another suggestion for future research around the topic of PA perspectives on
PGD would be to conduct a qualitative study, as opposed to quantitative. Researchers could
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interview PAs to study their attitudes toward PGD and reasons why they may agree or disagree
with the use of PGD. Interviews could allow for open ended questions and responses, creating
broader results and explanations. Participants may be more honest and variant in their answers
and give insight into their perspectives beyond the condensed survey question answers.
Conclusion
The purpose of this study was to assess physician assistant approval and disapproval of
PGD for Mendelian vs. Non-Mendelian disorders. Additionally, the survey aimed to explore
common reasons why PAs approve or disapprove of PGD utilization. A 12-question survey was
sent to CAPA members through a link posted on their organization website and to KAPA
members through their email. A total of 14 surveys were completed by PAs who are members of
KAPA and practicing in Kansas. Data revealed no statistical significance between approval and
disapproval of PGD for Mendelian conditions as responses were varied. Regarding PGD
approval and disapproval for Non-Mendelian traits, data revealed statistical significance due to
the fact that all participants responded with disagree or had no opinion.
In general, trends from the results showed that participants most commonly approved of
PGD utilization to screen for diseases that are fatal in the first few years of life. Most
commonly, participants agreed to PGD use on the basis that couples should be able to make their
own decisions about having a child. Overall trends for opinions on PGD for Mendelian
conditions cannot be concluded as responses were variable. Participants primarily disapproved
of, with a couple having had no opinion for PGD utilization for Non-Mendelian traits including
gender selection, physical characteristics, personality traits, or sexuality. The most common
reason participants disagreed with using PGD for such screening was the belief that PGD
interferes with nature and places providers in the role of “playing God.” Limitations and
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delimitations of the study included the limited population size, distribution methods of the
survey, narrow survey questions and answers, PA association members and participants’
knowledge and opinions towards PGD, and the fact that PGD is controversial topic.
The significance of this research does not lie in impressive statistics nor astounding
sample size numbers. Rather, this research serves as opening the door to potential avenues of
future research. With respect to advancements in genetic medicine, PGD will likely become
more popular and more prevalent within medicine. PAs should know how to address PGD use in
patient care, and be able to refer patients to the right provider if they are uncomfortable or unable
to offer their patients appropriate care and professional perspectives surrounding PGD. It can be
concluded that a variety of opinions surround PGD use. Providers need to be educated on PGD
use, and respect their patients’ wishes and healthcare needs. Future research could shed light on
to where PAs need further education about genetics and PGD, enabling positive growth in the
future of medicine.
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Dr. William Winkelman’s Survey Tool
Section 1

When a woman’s egg and a man’s sperm join, they form a fertilized egg which then grows into
an embryo and can eventually lead to a pregnancy. This part of the survey asks you your
opinions on whether doctors should provide genetic diagnosis of human embryos before
pregnancy.
Preimplantation genetic diagnosis, or “PGD” is a procedure that takes place in a lab with test
tubes and can be used to identify specific diseases in embryos before a woman gets pregnant.
PGD can detect diseases that are fatal in the first few years of life as well as diseases that can
cause significant disabilities throughout a person’s life. Patients who decide to undergo PGD
must first agree to undergo in vitro fertilization where the woman’s egg and the man’s sperm are
combined outside the human body in order to form a fertilized egg which then grows into an
embryo. In PGD, one or two cells from an embryo are removed and tested for various diseases. If
a specific disease is identified then the embryo is discarded. If there is no identified disease then
the embryo is placed in the woman’s uterus with the ultimate goal of a healthy baby.
Questions
In the following questions, please indicate the answer that best reflects your own personal
beliefs. There is no right or wrong answer.
1. Doctors should be able to perform PGD to screen for diseases that are fatal in the first
few years of life.
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
2. Doctors should be able to perform PGD to screen for diseases that cause lifelong
disability such as mental retardation or deafness.
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
3. Doctors should be able to perform PGD to screen for diseases that may not occur until
later in life, such as diseases that place an individual at a high risk of cancer during
adulthood.
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
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4. If you “agree” or “strongly agree” to questions 2, 3 or 4 that doctors should be able to
perform PGD, which of the following statements best describes your reasons? (Please
select all that apply)
a. Couples should be able to make their own decisions about having a child
b. PGD improves the chances that a couple will have a healthy child
c. PGD will lower healthcare costs and may result in a better society
d. PGD can eliminate certain genetic diseases forever
e. Other, please specify:
f.
5. If you “disagree” or “strongly disagree” to questions 2, 3 or 4 that doctors should be able
to perform PGD, which of the following statements best describes your reasons? (Please
select all that apply)
a. PGD leads to the unnecessary destruction of embryos
b. PGD promotes discrimination against people with certain diseases
c. PGD interferes with nature and places doctors in the role of “playing God”
d. Widespread use of PGD may lead to unforeseen consequences
e. There is no regulation of PGD
f. Other, please specify:
g.
Additional background information for participants
While PGD is a procedure that is most commonly used to identify diseases, in the future it
potentially could be used to test for physical characteristics, personality traits, abilities, or sexual
orientation. Again, please indicate the answer that best reflects your own personal beliefs. There
is no right or wrong answer.
6. Doctors should be able to perform PGD for sex selection
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
7. Doctors should be able to perform PGD to screen for physical characteristics such as height,
eye color or athleticism.
f. Strongly agree
g. Agree
h. Neither agree nor disagree
i. Disagree
j. Strongly disagree
8. Doctors should be able to perform PGD to screen for personality traits such as intelligence or
aggression.
k. Strongly agree
l. Agree
m. Neither agree nor disagree
n. Disagree
o. Strongly disagree
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9. Doctors should be able to perform PGD to screen for sexual orientation such as homosexuality
p. Strongly agree
q. Agree
r. Neither agree nor disagree
s. Disagree
t. Strongly disagree
10. If you “agree” or “strongly agree” to questions 7, 8, 9 or 10 that doctors should be able to use
of PGD for selection of ideal traits, which of the following statements best describes your
reasons? (Please select all that apply)
u. Couples should be able to make their own decisions about having a child
v. Selecting ideal traits will help a child lead a successful life
w. Selecting ideal traits will result in a better society
x. Other, please specify:
y.
11. If you “disagree” or “strongly disagree” to questions 7, 8, 9 or 10 that doctors should be able
to use of PGD for selection of ideal traits, which of the following statements best describes your
reasons? (Please select all that apply)
z. PGD leads to the unnecessary destruction of embryos
aa. PGD promotes discrimination against people with certain characteristics
bb. PGD interferes with nature and places doctors in the role of “playing God”
cc. Widespread use of PGD may lead to unforeseen consequences
dd. There is no regulation of PGD
ee. Other, please specify:
ff.
Section 2

This section asks you for some basic background information. This information is for research
reasons only. It will not be used to identify you in any way.
For each of the following questions, please select the answer that best describes you
1. What is your gender?
a. Male
b. Female
2. What is your age?
a. (Numerical values from 18 to 75)
3. What is your ethnicity?
a. Hispanic or Latino
b. Not Hispanic or Latino
4. What is your race? (select all that apply)
a. American Indian or Alaska Native
b. Asian
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c. Black or African American
d. Native Hawaiian or Pacific Islander
e. White
f. Other
5. In which state do you live?
a. (Dropdown menu of all 50 states)
6. What is your approximate household income?
a. $20,000 or less
b. $20,000–$40,000
c. $40,001–$60,000
d. $60,001–$80,000
e. More than $80,000
7. What is your religion?
a. Christian – Protestant
b. Christian – Catholic
c. Jewish
d. Muslim
e. Hindu
f. Atheist/Agnostic
g. Other, please specify:
h.
8. Which of the following best describes your level of education?
a. Some high school or less
b. High school diploma or GED
c. Some college
d. College degree
e. Some graduate school
f. Graduate or professional degree
9. Prior to this study have you ever heard of preimplantation genetic diagnosis (PGD)?
a. Yes
b. No
10. Do you personally know anyone with a genetic or developmental disorder?
a. Yes
b. No
11. Do you personally know anyone who required the help of assisted reproductive
technology to achieve a healthy pregnancy?
a. Yes
b. No
12. How many biological children do you have?
a. 0
b. 1
c. 2
d. 3
e. 4
f. More than 4
Thank you for taking the time to participate in our study.
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Current Researcher’s Adapted Survey Tool
Informed Consent:
You are invited to participate in a study that is being conducted by Minnesota Physician
Assistant Students from Bethel University’s Physician Assistant Program, which is a partial
fulfillment of the requirements for a Master’s Degree in Physician Assistant Studies. The
purpose of the study is to analyze the understandings, perspectives, and ethical considerations
physician assistants hold in relation to preimplantation genetic diagnosis (PGD). You were
selected as a possible participant in this study because you are a physician assistant practicing in
California, Kansas, or Virginia.
Participation in the study is voluntary. If you decide to participate, participation involves
a short, 10-minute online survey adapted by researchers from Bethel University’s PA Program.
The survey questions will ask about your understanding, utilization, and ethical implications of
PGD. If you feel uncomfortable in any way during the online survey, you have the right to skip
the question or discontinue the survey with no penalty.
No identifying information will be collected, and data will be stored on an encrypted
flashdrive and locked in a Bethel University Graduate Studies staff’s office. In any written
reports or publications, only aggregate data will be presented, in order to maintain anonymity.
Your decision whether or not to participate will not affect your future relations with Bethel
University, CAPA, KAPA, or VAPA in any way.
This research project has been reviewed and approved in accordance with Bethel
University’s Levels of Review for Research with Humans. If you have any questions about the
research and/or research participants’ rights or wish to report a research related injury, please call
the contacts listed below. If you so choose, a copy of this informed consent can be offered to you
to keep.
We understand that you have an extremely busy schedule and your time is limited. The
information that you provide is essential to the validity of this study. Thank you in advance for
your participation in this study. If you have any questions, please contact Research Chair:
Christina Hanson PA-C, 651-635-8042, Research Committee Member: Jeanne Szarzynski, 651635-8002, Researcher: Sarah Barnes, 952-843-8696, Researcher: Samantha Hamlin, 507-4400551, Researcher: Claire Johnson, 612-280-1282.
By continuing with the survey, you have read the information that is provided above, and
you are granting consent to participate in this research. Thank you again for your help.
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Section 1
Background information: When a woman’s egg and a man’s sperm join, they form a fertilized
egg which then grows into an embryo and can eventually lead to a pregnancy. This part of the
survey asks you your opinions on whether providers should provide genetic diagnosis of human
embryos before pregnancy.
Preimplantation genetic diagnosis, or “PGD” is a procedure that takes place in a laboratory,
where testing is conducted to identify specific diseases in embryos before implantation. PGD can
detect diseases that are fatal in the first few years of life as well as diseases that can cause
significant disabilities throughout a person’s life. Patients who decide to undergo PGD must first
agree to undergo in vitro fertilization. In PGD, one or two cells from an embryo are removed and
tested for various diseases. If a specific disease is identified then the embryo is discarded. If there
is no identified disease then the embryo is implanted.
In the following questions, please indicate the answer that best reflects your own personal
beliefs. There is no right or wrong answer.
1. Providers should be able to perform PGD to screen for diseases that are fatal in the first
few years of life.
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
2. Providers should be able to perform PGD to screen for diseases that cause lifelong
disability such as mental retardation or deafness.
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
3. Providers should be able to perform PGD to screen for diseases that may not occur until
later in life, such as diseases that place an individual at a high risk of cancer during
adulthood.
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
4. If you “agree” or “strongly agree” to questions 1, 2, or 3 that providers should be able to
perform PGD, which of the following statements best describes your reasons? (Please
select all that apply)
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a.
b.
c.
d.

Couples should be able to make their own decisions about having a child
PGD improves the chances that a couple will have a healthy child
PGD will lower healthcare costs and may result in a better society
PGD can eliminate certain genetic diseases forever

5. If you “disagree” or “strongly disagree” to questions 1, 2, or 3 that providers should be
able to perform PGD, which of the following statements best describes your reasons?
(Please select all that apply)
a. PGD leads to the unnecessary destruction of embryos
b. PGD promotes discrimination against people with certain diseases
c. PGD interferes with nature and places doctors in the role of “playing God”
d. Widespread use of PGD may lead to unforeseen consequences
e. There is no regulation of PGD
6. Providers should be able to perform PGD for sex selection.
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
7. Providers should be able to perform PGD to screen for physical characteristics such as height,
eye color or athleticism.
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
8. Providers should be able to perform PGD to screen for personality traits such as intelligence or
aggression.
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
9. Providers should be able to perform PGD to screen for sexual orientation such as
homosexuality
a. Strongly agree
b. Agree
c. Neither agree nor disagree
d. Disagree
e. Strongly disagree
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10. If you “agree” or “strongly agree” to questions 6, 7, 8, or 9 that providers should be able to
use of PGD for selection of ideal traits, which of the following statements best describes your
reasons? (Please select all that apply)
a. Couples should be able to make their own decisions about having a child
b. Selecting ideal traits will help a child lead a successful life
c. Selecting ideal traits will result in a better society
11. If you “disagree” or “strongly disagree” to questions 6, 7, 8, or 9 that providers should be
able to use of PGD for selection of ideal traits, which of the following statements best describes
your reasons? (Please select all that apply)
a. PGD leads to the unnecessary destruction of embryos
b. PGD promotes discrimination against people with certain characteristics
c. PGD interferes with nature and places doctors in the role of “playing God”
d. Widespread use of PGD may lead to unforeseen consequences
e. There is no regulation of PGD
Section 2
This section asks you for some basic background information. This information is for research
reasons only. It will not be used to identify you in any way.
For the following question, please select the answer that best describes you
12. What Academy of Physician Assistants state are you a member of?
a. California
b. Kansas
c. Virginia
Thank you for taking the time to participate in our study.
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Correspondences with CAPA, KAPA, VAPA
CAPA:
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KAPA:
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VAPA:
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Informed Consent, Statement of Confidentiality, and Study’s Purpose:

You are invited to participate in a study that is being conducted by Minnesota Physician
Assistant Students from Bethel University’s Physician Assistant Program, which is a partial
fulfillment of the requirements for a Master’s Degree in Physician Assistant Studies. The
purpose of the study is to analyze the understandings, perspectives, and ethical considerations
physician assistants hold in relation to preimplantation genetic diagnosis (PGD). You were
selected as a possible participant in this study because you are a physician assistant practicing in
California, Kansas, or Virginia.
Participation in the study is voluntary. If you decide to participate, participation involves
a short, 10-minute online survey adapted by researchers from Bethel University’s PA Program.
The survey questions will ask about your understanding, utilization, and ethical implications of
PGD. If you feel uncomfortable in any way during the online survey, you have the right to skip
the question or discontinue the survey with no penalty.
No identifying information will be collected, and data will be stored on an encrypted
flashdrive and locked in a Bethel University Graduate Studies staff’s office. In any written
reports or publications, only aggregate data will be presented, in order to maintain anonymity.
Your decision whether or not to participate will not affect your future relations with Bethel
University, CAPA, KAPA, or VAPA in any way.
This research project has been reviewed and approved in accordance with Bethel
University’s Levels of Review for Research with Humans. If you have any questions about the
research and/or research participants’ rights or wish to report a research related injury, please call
the contacts listed below. If you so choose, a copy of this informed consent can be offered to you
to keep.
We understand that you have an extremely busy schedule and your time is limited. The
information that you provide is essential to the validity of this study. Thank you in advance for
your participation in this study. If you have any questions, please contact Research Chair:
Christina Hanson PA-C, 651-635-8042, Research Committee Member: Jeanne Szarzynski, 651635-8002, Researcher: Sarah Barnes, 952-843-8696, Researcher: Samantha Hamlin, 507-4400551, Researcher: Claire Johnson, 612-280-1282.
By continuing with the survey, you have read the information that is provided above, and
you are granting consent to participate in this research. Thank you again for your help.

